TOPCHOICE MEDICAL CORPORATION Releases 2025 Annual Report and Q1 2026 Report; Geistlich Plans to Build Its First Oral Biomaterial Intelligent Manufacturing Base Outside Europe in Suzhou; Bribery in Medical and Oth…

Tong Ce Medical: 2025 Revenue Reaches 2.913 Billion Yuan, Implant and Pediatric Dentistry Incomes Both Decline

On April 17, 2026, Tong Ce Medical Co., Ltd. released its 2025 Annual Report and 2026 First Quarter Report. The reports show that the company achieved operating revenue of approximately 2.913 billion yuan in 2025, a year-on-year increase of 1.37%. The net profit attributable to shareholders of the listed company was 502 million yuan, up 0.19% year-on-year, while the net profit after deducting non-recurring gains and losses slightly decreased by 0.04%. In the first quarter of 2026, the company's revenue was 755 million yuan, and the net profit attributable to shareholders of the parent company was 187 million yuan, representing year-on-year growth of 1.43% and 1.66%, respectively. Regarding income from various departments, the implant business revenue was 519 million yuan, down 2.08% year-on-year; orthodontics business revenue was 510 million yuan, up 7.63% year-on-year; and pediatric dentistry business revenue was 487 million yuan, down 2.69% year-on-year. As of March 31, 2026, the company's total assets were 6.239 billion yuan, total liabilities were 1.453 billion yuan, and net assets attributable to shareholders of the parent company were 4.421 billion yuan, an increase of 4.41% compared to the end of the previous year.

Geistlich Signs Agreement with Suzhou Industrial Park, Plans to Build First Oral Biomaterial Smart Manufacturing Base Outside Europe

On April 16, 2026, Geistlich Group officially signed an agreement with Suzhou Industrial Park. The group will invest in building its first self-owned brand oral biomaterial intelligent manufacturing base outside Switzerland within the park. This will introduce pillar products such as bone filling materials and absorbable membranes for localized production. It is reported that Geistlich Group will be located in BioBAY, the core biopharmaceutical park within Suzhou Industrial Park, with some products included in the localization scope. This marks the first time in Geistlich's 175-year history that it has established a production and manufacturing base for its own oral biomaterial brand outside Switzerland. As of the time of reporting, Geistlich Group has not disclosed the specific investment amount or construction timeline for this smart manufacturing base project.

Shining3D Tech Co., Ltd. Plans to Use Up to 1.6 Billion Yuan in Idle Own Funds for Cash Management, Purchasing Financial Products

On April 10, 2026, the board of directors of Shining3D Tech Co., Ltd. reviewed and approved the use of up to 1.6 billion yuan in idle own funds for cash management to purchase financial products with high safety and good liquidity. This proposal needs to be submitted to the shareholders' meeting on May 8, 2026, for review. The funds will come from the company's and its subsidiaries' own funds, with a rolling validity period of 12 months. The announcement clarifies that this financial management activity does not constitute a connected transaction, and the finance department will ensure fund liquidity and safety. Additionally, the company is advancing its listing on the Beijing Stock Exchange (BSE), planning to raise 550 million yuan, primarily for the research and development of high-precision digital implantology technology in dentistry.

Haili Biology Plans to Establish a Second-Tier Subsidiary to Centrally Manage 7 Jinboli Dental Chain Outlets in Yangzhou and Changzhou

On April 15, 2026, Haili Biology announced its plan to invest 15 million yuan through its controlling subsidiary, Ruisheng Biology, to establish a second-tier subsidiary named Haili Oral, which will centrally manage 7 Jinboli brand dental chain outlets in Yangzhou and Changzhou. The seven outlets include one dental hospital and six dental clinics. They are expected to increase revenue by approximately 100 million yuan and net profit by over 7 million yuan in 2026. The establishment aims to strengthen centralized control over the dental chain business and enhance operational efficiency. The transaction has been reviewed and approved by the board of directors. However, the relevant industrial and commercial transfer procedures have not been fully completed, and uncertainties remain.

Meihao Medical 2025 Annual Report: Revenue Exceeds 100 Million Yuan, Up 36.2% YoY, Pre-Tax Loss Narrows by Approximately 46.5%

On March 30, 2026, Meihao Group released its 2025 annual performance announcement. The report shows that the group achieved total revenue of approximately 101.7 million yuan in the 2025 fiscal year, a 36.2% increase from 74.68 million yuan in 2024. The loss attributable to owners of the parent company narrowed from 32.424 million yuan to 14.341 million yuan. The pre-tax loss was about 16.10 million yuan, narrowing by approximately 46.5%. Implant dentistry revenue grew by 125.8%, primarily driven by demand release following the VBP policy for dental implants. Meihao operates 6 private dental hospitals and 1 clinic in Wenzhou, with the number of active patients increasing to 66,800. The group plans to seek new growth points through international expansion and has already invested in a Thai assisted reproductive services company.

Shining3D Releases Three-Year Verification Report: Received 74.9385 Million Yuan in Government Subsidies in 2025, Advancing BSE IPO

On April 13, 2026, Shining3D Tech Co., Ltd. released the "Verification Report on Non-recurring Gains and Losses for the Past Three Years." The report shows that the company received government subsidies totaling 74.9385 million yuan in 2025, a year-on-year increase of 56.85%. The company is currently in the suspended review stage of its IPO on the Beijing Stock Exchange (BSE). The subsidies were mainly used for R&D, with R&D expense subsidies amounting to 28.3019 million yuan. The net profit attributable to shareholders of the parent company reached 425 million yuan in 2025, with subsidies accounting for approximately 17.6%. As of the report, the company plans to raise 550 million yuan, with about 29% allocated to the research and development project for high-precision digital implantology technology in dentistry.

Arrail Group Revises Loan Agreement with Zou Qifang's Wholly-Owned Company: Principal Reduced to $6.4875 Million, Repayment Period Extended by Three Years

On April 10, 2026, Arrail Group signed the fourth amended loan agreement with Beier Holdings Limited, a wholly-owned company of its controlling shareholder Zou Qifang. The loan principal was reduced from $7.5 million to $6.4875 million, and the loan term was extended from 42 months to 78 months. This loan was primarily used to fund a share acquisition in December 2017, with the interest rate remaining at an annual rate of 5.5%. As of the announcement date, the borrower had repaid approximately $4.51 million of the principal. Due to the failure to secure third-party financing, the borrower paid default interest for 9 days. Both parties agreed to release 18 million pledged shares, with the remaining 33,337,150 shares continuing to be pledged. These shares are valued at approximately HK$61 million (about $7.79 million), sufficient to cover the outstanding loan. Arrail Group's shares remain suspended from trading.

Weigao Group Issues Public Apology for Million-Yuan Bribery Case: Employee Sentenced, Involved Kickbacks to 18 Departments

On April 9, 2026, Weigao Group issued an apology statement on the official website of the Yunnan Provincial Medical Security Bureau. The statement was due to a salesperson's involvement in bribery during the sales process of medical devices, potentially leading to a credit rating downgrade. The investigation revealed that between 2011 and 2020, the salesperson bribed staff at Pu'er City People's Hospital with cash totaling 395,000 yuan, $9,900 USD, and a 200-gram gold bar. Additionally, kickbacks totaling 1.1912 million yuan were given to 18 departments. The salesperson was sentenced to two years and six months in prison for bribery and fined 200,000 yuan. Weigao Group has terminated the employment contract of the involved salesperson and reduced the sales prices of related products to actively correct the impact of the credit breach and avoid being listed on the "seriously dishonest" list.

"Two Supremes" Update Interpretation on Graft and Bribery, Clearly Including Bribery in Medical and Other Fields as Aggravating Circumstances

On April 10, 2026, the Supreme People's Court and the Supreme People's Procuratorate jointly issued the "Interpretation (II) on Several Issues Concerning the Application of Law in Handling Criminal Cases of Graft and Bribery," effective from May 1, 2026. Interpretation (II) further refines the rules for identifying bribery in fields such as healthcare, explicitly stating that bribery acts in these fields will be severely pursued. Specifically, if an individual offers bribes between 100,000 and 200,000 yuan, or a unit offers bribes between 200,000 and 400,000 yuan, and it involves illegal or criminal activities, criminal liability may be pursued according to law. The conviction and sentencing standards for the crimes of accepting bribes and offering bribes by non-state personnel will be the same as those for public official bribery crimes, aiming to achieve equal protection for enterprises of different ownership types.

General Offices of CPC Central Committee and State Council Issue Opinion: Strictly Control Establishment of Competitive Enterprises, Consciously Resist "Involutionary" Competition

On April 13, 2026, the General Office of the Communist Party of China Central Committee and the General Office of the State Council issued the "Opinions on Promoting the Deepening Reform of Industry Associations and Chambers of Commerce," providing comprehensive guidance for their transformation and development. The opinion emphasizes strict control over the establishment of enterprises that directly compete with members. Industry associations and their responsible persons are prohibited from holding positions or receiving remuneration in such established enterprises. The document also calls for optimizing organizational structures, focusing on cultivating associations and chambers that align with major national strategies, and supporting the lawful establishment of associations and chambers in strategic emerging industries and other fields. Furthermore, the opinion encourages industry associations to participate in international exchanges and promote mutual recognition between domestic and international standards.

National Bureau of Statistics: Q1 Healthcare CPI Up 1.8% YoY, GDP Grows 5.0%

On April 16, 2026, the National Bureau of Statistics released data on the national economic performance for the first quarter of 2026. The Gross Domestic Product (GDP) reached 33.4193 trillion yuan, a year-on-year increase of 5.0%, with the growth rate accelerating by 0.5 percentage points compared to the fourth quarter of the previous year. During the same period, the Consumer Price Index (CPI) rose by 0.9% year-on-year, while the healthcare CPI increased by 1.8%. In the first quarter, the national per capita disposable income was 12,782 yuan, a nominal increase of 4.9% and a real increase of 4.0% year-on-year. Total retail sales of consumer goods reached 12.7695 trillion yuan, up 2.4% year-on-year. Industrial added value grew by 6.1% year-on-year, with high-tech manufacturing added value increasing by 12.5%. Total goods import and export volume was 11.838 trillion yuan, a year-on-year increase of 15.0%. As of the report, the National Bureau of Statistics has not yet disclosed sub-item data for the manufacturing industry of equipment and appliances for dental use.

Medical Diagnostics Company OraLiva Launches AI-Powered Oral Cancer Detection Product

Medical diagnostics company OraLiva has launched an AI-powered product for detecting oral cancer and oral lesions. It has partnered with Delta Dental companies in Michigan, Ohio, Indiana, and North Carolina to include this detection in insurance coverage. The detection is based on an NIH-sponsored prospective study on oral potentially malignant disorders, involving 999 patients and analyzing over 13 million cells. OraLiva's detection model combines microfluidic cytology, digital imaging, and artificial intelligence technology to assess oral lesion risk and identify lesions requiring referral or monitoring. The program can be reimbursed using CDT code D7288 in the partner states and is expected to expand to more states within the year.

SprintRay's Flexible Denture Resin Apex Flex Receives FDA Class II Certification, Claims In-Office Same-Day Delivery in About 2 Hours

In April 2026, SprintRay released Apex Flex, a flexible partial denture resin that has received FDA Class II certification. It supports in-office 3D printing, enabling same-day delivery in approximately 2 hours. The material has a flexural strength of ≥26.5 MPa and an elongation at break of ≥50%, making it suitable for tooth-supported partial denture fabrication. Compared to traditional methods, the Apex Flex digital workflow can shorten production cycles and enhance process control. The company notes that the material should be used with caution in specific situations to avoid affecting stability.

MIT Introduces AI 3D Printing Preview Tool, Generates Photorealistic Previews in About a Minute, Matching Restoration Color to Natural Teeth

On April 1, 2026, the Massachusetts Institute of Technology (MIT), in collaboration with Princeton University and the Gwangju Institute of Science and Technology in South Korea, released an AI 3D printing preview tool named VisiPrint. Using computer vision models and generative AI, the tool allows users to upload screenshots from slicing software and material photos to generate photorealistic previews in about a minute. The MIT research team pointed out that approximately one-third of 3D printing materials end up in landfills due to discarded prototypes. In dentistry, VisiPrint's application can ensure precise color matching between restorations like temporary crowns and bridges and the patient's natural teeth, achieving a 100% success rate in tests. Currently, VisiPrint is available as a standalone UI and an Ultimaker Cura plugin, with plans to further optimize detail issues in the future.

American Dental Association Updates 2027 CDT Codes: Adds 28 New Items, Covering Implant Restoration and Orofacial Pain Management

On April 14, 2026, the American Dental Association (ADA) released the CDT 2027 code changes, involving 67 adjustments, of which 28 are new codes. This update includes new dedicated codes for implant removal and healing cap placement in the implant field. In the restorative field, the scope of code D2390 has been expanded from anterior teeth to all teeth. Additionally, new codes for injection closure in the orofacial pain management field have been added. CDT 2027 is expected to be officially released in the fall of 2026 and will take effect on January 1, 2027. The deadline for change requests for CDT 2028 is November 1, 2026.

First Confirmation: Stem Cells from Human Exfoliated Deciduous Teeth May Treat Chronic-Stage Cerebral Palsy

Nagoya University in Japan released research that, for the first time in an animal model, confirmed that intravenous injection of stem cells from human exfoliated deciduous teeth (SHED) can improve motor, learning, and memory functions in chronic-stage cerebral palsy. The study used the Rice-Vannucci method to induce unilateral hypoxic-ischemic brain injury in newborn rats and treated them with intravenous SHED injections during the chronic phase at 5, 7, and 9 weeks of age. Experimental results showed that rats in the SHED group outperformed the control group in gait scores, coordinated motor ability, and learning and memory capabilities. Currently, Nagoya University Hospital has initiated clinical research to evaluate the safety and tolerability of autologous SHED intravenous injection in children with cerebral palsy. Due to species differences between rats and humans, the conclusions require further validation.

Global Survey: Limited Adoption of Immersive Technologies in Dental Education, Postgraduate Usage of Dental Haptic VR Only 10%

On April 11, 2026, a global survey conducted by a research team from 28 institutions including the University of Liverpool and the University of Hong Kong, and published in the Journal of Dental Education, revealed that traditional simulation methods still account for about 80% of clinical training time in dentistry. The usage rate of haptic virtual reality (HVR) in postgraduate institutions is only 10%. The survey was conducted from July to August 2025, covering 115 institutions across 57 countries. Among 89 respondents who provided feedback on implementation barriers, 66.3% cited a lack of resources as the main obstacle. The frequency of HVR use in undergraduate programs in high-income countries is significantly higher than in low-income countries. If this gap continues to widen, it will create a structural disparity in clinical preparedness in dentistry. The researchers recommend that educational institutions and policymakers collaborate to promote sustainable adoption pathways.